Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 19;23(18):10946. doi: 10.3390/ijms231810946

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Effector-memory (EM) T cells show a higher Th1 and lower Th2 phenotype in patients with CMV viremia after aHSCT. PBMCs were stained with fluorophore-conjugated antibodies and analyzed by flow cytometry. In (A) the gating strategy is depicted in one representative example. (B) Th1 and Th2 phenotypes of EM CD4+ T cells before and at 1, 3, 6, and 12 months after aHSCT. For CMV viremia group, n = 5, 5, 4, 5, 4, for no CMV viremia group, n = 21, 16, 15, 22, 21. To detect significant differences, an unpaired Wilcoxon signed-rank test was used, significance levels were * for p ≤ 0.05, and ** for p ≤ 0.01.

Effector-memory (EM) T cells show a higher Th1 and lower Th2 phenotype in patients with CMV viremia after aHSCT. PBMCs were stained with fluorophore-conjugated antibodies and analyzed by flow cytometry. In (A) the gating strategy is depicted in one representative example. (B) Th1 and Th2 phenotypes of EM CD4+ T cells before and at 1, 3, 6, and 12 months after aHSCT. For CMV viremia group, n = 5, 5, 4, 5, 4, for no CMV viremia group, n = 21, 16, 15, 22, 21. To detect significant differences, an unpaired Wilcoxon signed-rank test was used, significance levels were * for p ≤ 0.05, and ** for p ≤ 0.01.